Alcyomics Ltd. Industries
-
Medical / Health Care
-
-
-
The key FDA’s and EMA’s biosafety concerns (1,2) are the potential for cell based tumorigenicity, immunogenicity, infectious disease, and or genetic modification. Cellular therapies are aimed at specific disease types and to proliferate and differentiate into the desired cell type without causing unnecessary and potentially dangerous proliferation into cancer cells or unwanted immunogenicity causing damage in surrounding tissue.
Determining adverse immune responses to monoclonal antibodies.
Skimune® can predict first-in-man hypersensitivity or adverse immune reactions to small molecule therapeutics.